TY - JOUR
T1 - Association of cortical and subcortical β-amyloid with standardized measures of depressive and anxiety symptoms in adults without dementia
AU - Krell-Roesch, Janina
AU - Syrjanen, Jeremy A.
AU - Rakusa, Martin
AU - Vemuri, Prashanthi
AU - Machulda, Mary M.
AU - Kremers, Walter K.
AU - Mielke, Michelle M.
AU - Lowe, Val J.
AU - Jack, Clifford R.
AU - Knopman, David S.
AU - Stokin, Gorazd B.
AU - Petersen, Ronald C.
AU - Vassilaki, Maria
AU - Geda, Yonas E.
N1 - Funding Information:
Supported by NIH (grants R01 AG057708, U01 AG006786, P50 AG016574, R01 AG034676, R01 AG011378, and R01 AG041851), NIMH (grant K01 MH068351), and the National Institute of Neurological Disorders and Stroke (grant R01 NS097495), as well as the Arizona Alzheimer’s Consortium, the Edli Foundation, the Gerald and Henrietta Rauenhorst Foundation, the Mayo Foundation for Medical Education and Research, Project LQ1605 from the National Program of Sustainability II (MEYS CR), the Robert Wood Johnson Foundation, and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer’s Disease Research Program.
Funding Information:
Supported by NIH (grants R01 AG057708, U01 AG006786, P50 AG016574, R01 AG034676, R01 AG011378, and R01 AG041851), NIMH (grant K01 MH068351), and the National Institute of Neurological Disorders and Stroke (grant R01 NS097495), as well as the Arizona Alz-heimer?s Consortium, the Edli Foundation, the Gerald and Henrietta Rauenhorst Foundation, the Mayo Foundation for Medical Education and Research, Project LQ1605 from the National Program of Sustain-ability II (MEYS CR), the Robert Wood Johnson Foundation, and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer?s Disease Research Program. Dr. Rakusa has received a research grant partially funded by the Ful-bright Program. Dr. Vemuri receives research funding from NIH. Dr. Machulda receives research funding from NIH. Dr. Kremers receives research funding from Astra Zeneca, Biogen, the Department of De-fense, NIH, and Roche. Dr. Mielke has served as a consultant to Eli Lilly; she has received unrestricted research grants from Biogen, Lundbeck, and Roche; and she receives research funding from the Department of Defense, the National Institute on Aging, and NIH. Dr. Lowe serves as a consultant to Bayer Schering Pharma, Merck Research, and Piramal Life Sciences and receives research support from AVID Radiopharmaceuti-cals, GE Healthcare, and Siemens Molecular Imaging. Dr. Jack serves as a consultant to Lily and serves on an independent data monitoring board for Roche. Dr. Knopman serves on a data safety monitoring board for the Dominantly Inherited Alzheimer Network study and is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California. Dr. Petersen serves as a consultant to Biogen, GE Healthcare, Genentech, Merck, and Roche and receives royalties from Oxford University Press. Dr. Vassilaki has received research funding from Roche and currently receives research funding from Biogen and NIH, and she has equity ownership in Abbott Labo-ratories, Amgen, Johnson and Johnson, and Medtronic. Dr. Geda receives research funding from NIH and Roche and served on the advisory board of Lundbeck.
Publisher Copyright:
© 2021, American Psychiatric Association. All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Objective: The purpose of this study was to test the hy-pothesis that subcortical β-amyloid (Aβ) deposition was associated with elevated scores on standardized measures of depressive and anxiety symptoms when compared with cortical (Aβ) deposition in persons without dementia. Methods: The authors performed a cross-sectional study, derived from the population-based Mayo Clinic Study of Aging, comprising participants aged ≥70 years (N=1,022; 55% males; 28% apolipoprotein E [APOE] ε4 carriers; without cognitive impairment, N=842; mild cognitive impairment; N=180). To assess Aβ deposition in cortical and subcortical (the amygdala, striatum, and thalamus) regions, participants underwent Pittsburgh Compound B positron emission to-mography (PiB-PET) and completed the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI). The investigators ran linear regression models to examine the association between PiB-PET standardized uptake value ratios (SUVRs) in the neocortex and subcortical regions and depressive and anxiety symptoms (BDI-II and BAI total scores). Models were adjusted for age, sex, education level, and APOE ε4 carrier status and stratified by cognitive status (without cognitive impairment, mild cognitive impairment). Results: Cortical PiB-PET SUVRs were associated with depressive symptoms (β=0.57 [SE=0.13], p<0.001) and anxiety symptoms (β=0.34 [SE=0.13], p=0.011). PiB-PET SUVRs in the amygdala were associated only with depressive symptoms (β=0.80 [SE=0.26], p=0.002). PiB-PET SUVRs in the striatum and thalamus were associated with depressive symptoms (striatum: β=0.69 [SE=0.18], p<0.001; thalamus: β=0.61 [SE=0.24], p=0.011) and anxiety symptoms (striatum: β=0.56 [SE=0.18], p=0.002; thalamus: β=0.65 [SE=0.24], p=0.008). In the mild cognitive impairment subsample, Aβ deposition, regardless of neuroanatomic location, was associated with depressive symptoms but not anxiety symptoms. Conclusions: Elevated amyloid deposition in cortical and subcortical brain regions was associated with higher depressive and anxiety symptoms, although these findings did not significantly differ by cortical versus subcortical Aβ de-position. This cross-sectional observation needs to be con-firmed by a longitudinal study.
AB - Objective: The purpose of this study was to test the hy-pothesis that subcortical β-amyloid (Aβ) deposition was associated with elevated scores on standardized measures of depressive and anxiety symptoms when compared with cortical (Aβ) deposition in persons without dementia. Methods: The authors performed a cross-sectional study, derived from the population-based Mayo Clinic Study of Aging, comprising participants aged ≥70 years (N=1,022; 55% males; 28% apolipoprotein E [APOE] ε4 carriers; without cognitive impairment, N=842; mild cognitive impairment; N=180). To assess Aβ deposition in cortical and subcortical (the amygdala, striatum, and thalamus) regions, participants underwent Pittsburgh Compound B positron emission to-mography (PiB-PET) and completed the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI). The investigators ran linear regression models to examine the association between PiB-PET standardized uptake value ratios (SUVRs) in the neocortex and subcortical regions and depressive and anxiety symptoms (BDI-II and BAI total scores). Models were adjusted for age, sex, education level, and APOE ε4 carrier status and stratified by cognitive status (without cognitive impairment, mild cognitive impairment). Results: Cortical PiB-PET SUVRs were associated with depressive symptoms (β=0.57 [SE=0.13], p<0.001) and anxiety symptoms (β=0.34 [SE=0.13], p=0.011). PiB-PET SUVRs in the amygdala were associated only with depressive symptoms (β=0.80 [SE=0.26], p=0.002). PiB-PET SUVRs in the striatum and thalamus were associated with depressive symptoms (striatum: β=0.69 [SE=0.18], p<0.001; thalamus: β=0.61 [SE=0.24], p=0.011) and anxiety symptoms (striatum: β=0.56 [SE=0.18], p=0.002; thalamus: β=0.65 [SE=0.24], p=0.008). In the mild cognitive impairment subsample, Aβ deposition, regardless of neuroanatomic location, was associated with depressive symptoms but not anxiety symptoms. Conclusions: Elevated amyloid deposition in cortical and subcortical brain regions was associated with higher depressive and anxiety symptoms, although these findings did not significantly differ by cortical versus subcortical Aβ de-position. This cross-sectional observation needs to be con-firmed by a longitudinal study.
UR - http://www.scopus.com/inward/record.url?scp=85099744752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099744752&partnerID=8YFLogxK
U2 - 10.1176/appi.neuropsych.20050103
DO - 10.1176/appi.neuropsych.20050103
M3 - Article
C2 - 33086924
AN - SCOPUS:85099744752
SN - 0895-0172
VL - 33
SP - 64
EP - 71
JO - Journal of Neuropsychiatry and Clinical Neurosciences
JF - Journal of Neuropsychiatry and Clinical Neurosciences
IS - 1
ER -